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Objectives: Encompassing a group of cancers originating from the upper aero-
digestive tract, head and neck cancers are ranked in the top ten for both inci-
dence and mortality among all malignancies globally. This study aimed to estimate 
trends in total secondary care costs associated with the treatment of head and 
neck cancers in England from 2006/2007 to 2010/2011. MethOds: Data on inpa-
tient and outpatient activity associated with oropharyngeal, oral cavity and laryn-
geal cancer was extracted from the Hospital Episode Statistics (HES) database. 
After grouping inpatient episodes into spells, a single Healthcare Resource Group 
(HRG) was derived for each and then cross-referenced with the National Tariff 
2010/11 to estimate the associated cost. For specific types of therapy, including 
chemotherapy and radiotherapy, HRG definitions were cross-referenced with the 
National Reference Costs for the latest available year and inflated using the PCI 
index. Outpatient costs were estimated by grouping consultations by treatment 
speciality. Results: The total cost of treatment for all cancers over the entire 
period was estimated to be around £309 million, at 2011 prices. Inpatient care 
covered by bundled HRGs accounted for over 90% of this cost, at £280 million. Total 
costs due to oropharyngeal cancer were slightly higher than those estimated for 
laryngeal and oral cancer, costing £115 million (37.06%), £96 million (31.15%) and 
£98 million (31.79%) respectively. There was, generally, an increasing trend in the 
secondary care burden of all three cancers. Annual costs and patient numbers 
increased the most for oropharyngeal cancer, with annual inpatient costs increas-
ing from £16,576,046 in 2006/07 to £28,467,016 in 2010/11. cOnclusiOns: This 
study indicates that there is a significant, and increasing, health and economic 
burden associated with head and neck cancers in England, highlighting the need 
for preventative programmes.
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Objectives: During chemotherapy, a majority of patients experience treatment-
related adverse-events (TEAEs). However, the number of patients requiring treat-
ment and/or hospitalization (T&H) for managing TEAEs is significantly lower. The 
objective of this study was to evaluate economic burden of TEAEs in third line 
Metastatic Breast Cancer (MBC) patients. MethOds: A post-hoc analysis was con-
ducted on Phase 3 clinical trial of eribulin vs. Treatment of Physician’s Choice (TPC) 
in MBC patients with two prior chemotherapy regimens including anthracycline and 
taxane. TPC included capecitabine, gemcitabine, vinorelbine, docetaxel and pacli-
taxel. Grade 3&4 TEAEs which were observed in ≥ 5% of patients were considered. 
Patients who required T&H for managing TEAEs were further studied. Duration and 
costs associated with T&H were obtained from a micro-costing study where UK-NHS 
tariffs for each cost unit were applied. TEAE clinical trial frequency data for each 
treatment were annualized prior to cost evaluation, based on treatment duration 
(113 days for eribulin and 68 days for TPC patients). Results: Only a small propor-
tion of patients who experienced TEAEs required T&H. The frequencies of TEAEs 
experienced vs. TEAEs that required T&H for most commonly observed TEAEs were 
as follows: neutropenia (Eribulin: 45.2% vs. 14.5%; TPC: 21.1% vs. 5.3%), leukopenia 
(Eribulin: 13.9% vs 4.2%; TPC: 5.7% vs. 1.6%), peripheral-neuropathy (Eribulin: 8.2% 
vs. 3.8%; TPC: 2.0% vs. 0.4%) and asthenia/fatigue (Eribulin: 8.8% vs. 1.6%; TPC: 10.1% 
vs. 2.0%). Monthly TEAEs requiring T&H rates were Eribulin: 19.83%, TPC: 23.67%. 
Average annual costs for management of TEAEs were £2,621 for eribulin vs. £2,740 
for TPC patients. cOnclusiOns: Economic burden of toxicities in MBC patients 
may be lower than expected as very few TEAEs require T&H. This study may have 
led to omission of rare but costly AEs because of the patient selection criteria used. 
Using individual treatments as comparators instead of TPC may have brought addi-
tional clarity to the results. Further research is warranted to validate the findings.
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intROductiOn: Lung cancer is a highly prevalent condition with non-small 
cell lung cancer (NSCLC) representing ~80%. Given its high prevalence and poor 
survival rates, it is important to understand costs associated with NSCLC treat-
ment. Objectives: To carry out a study similar to the study by Ramsey (2008) in 
three European countries: France, Germany and UK. MethOds: Three similar 
administrative databases were accessed: Hospital Episode Statistics (England), 
Gesundheitsforen Leipzig (Germany), French Hospital Discharge system (France), 
using ICD-9/10 codes and treatment/surgery algorithms to identify NSCLC patients. 
An incidence population of NSCLC patients was obtained using an index year (rang-
ing from 2007-2008), ensuring the absence of prior lung cancer (12-months). Data 
were extracted on treatment information, patient characteristics and disease stag-
ing. Average NSCLC treatments were estimated by age and severity. For England 
20,081 patients were identified, for France, 15,061, for Germany, 1,038. Results: 
In-patient length of stay was 8.9, 8.7 and 10.1 days for France, England, Germany 
respectively for the first year. Hospital in-patient costs in the first year amounted 
to € 11,667, € 11,363, € 5,985 for France, Germany and England respectively. In year 
two these were € 5,916 (France), € 6,568 (Germany) and € 1,156 (England). Hospital out-
patient costs were in year 1 and 2: € 2,313 - € 676 (France); € 1,925 - € 1,766 (Germany); 
€ 1,209 - € 834 (England). Medicine costs in year 1 and 2 amounted to: € 3,542 - € 321 
(France); € 4,488 - € 3,805 (Germany); € 8,593 yr1 only (England). Other costs reported 
Objectives: To examine the economic burden and health care utilizations 
of patients diagnosed with pancreatic cancer in the U. S. veteran popula-
tion. MethOds: A retrospective database analysis was performed using Veterans 
Health Administration Medical SAS data from 01OCT2007 through 30SEP2012. 
Patients diagnosed with pancreatic cancer were identified using International 
Classification of Disease 9thRevision Clinical Modification (ICD-9-CM) code 157. 
The first diagnosis date was defined as the index date. A group of patients with 
similar age, region, gender and index year but without a pancreatic cancer diag-
nosis were identified as the comparison group and matched by baseline Charlson 
Comorbidity Index scores. One year of continuous health plan enrollment was 
required before and after the index date for both groups. Study outcomes, includ-
ing health care costs and utilizations, were compared between pancreatic cancer 
and comparator groups using 1: 1 propensity score matching (PSM). Results: A 
total of 10,894 patients were identified for the pancreatic cancer and comparison 
cohorts. After applying a 1: 1 PSM, 3,671 patients were matched from each cohort, 
and the baseline characteristics were proportionate. Pancreatic cancer patients 
were more likely to have higher health care resource utilizations, including inpa-
tient admissions (38.03% vs. 2.18%, p< 0.0001), emergency room (ER) (30.67% vs. 
5.48%, p< 0.0001), physician office visits (98.39% vs. 57.91%, p< 0.0001) and pre-
scription fills (83.55% vs. 62.82%, p< 0.0001). Risk-adjusted health care costs were 
also higher for pancreatic cancer patients, including inpatient ($18,079 vs. $442, 
p< 0.0001), ER ($330 vs. $46, p< 0.0001), physician office ($5,600 vs. $1,106, p< 0.0001) 
and pharmacy costs ($2,244 vs. $321, p< 0.0001), resulting in higher total costs 
($26,503 vs. $1,977, p< 0.0001) relative to the comparator cohort. cOnclusiOns: 
During a period of 12 months, VHA patients diagnosed with pancreatic cancer 
reported higher health care resource utilization and costs than their matched 
controls.
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Objectives: To explore the resource use and costs for multiple myeloma (MM) 
in a systematic literature review. MethOds: We searched MEDLINE, Embase, the 
Cochrane Library, and EconLit for English-language studies published from January 1, 
2003 to May 16, 2013 that evaluated resource use and costs related to MM, includ-
ing relapsed or relapsed and refractory MM (R/RRMM). These studies underwent 
data abstraction and qualitative synthesis. Results: Thirteen primary studies in 
the US (n= 5), UK (n= 1), US and UK (n= 1), The Netherlands (n= 2), France (n= 1), Italy 
(n= 1), Sweden (n= 1), and Switzerland (n= 1) met the inclusion criteria. Three studies 
were in newly-diagnosed MM patients, one in newly-diagnosed and previously-
treated patients, and nine in R/RRMM. The key cost drivers in R/RMM (as percentages 
of total costs) were medications (32% to 66%), hospitalisations (15% to 35%), and 
adverse events/complications/comorbidities (6% to 42%). Among treatment-related 
adverse events in MM, neutropenia was the main cost driver, accounting for at 
least two-thirds of total costs for managing such events, followed by thrombocyto-
penia, anaemia, and infections. In addition, metastatic bone disease significantly 
increased direct treatment costs (+$57,720 per patient; 2004 USD) and accounted 
for 17% (€ 6,937 per patient; 2002 € ) of total MM treatment costs. Also, patients with 
progressive disease incurred costs over three times those in patients without disease 
progression after initial treatment ($837 vs. $237 PPPM [2010 USD]). cOnclusiOns: 
The primary drivers of MM management costs are medication, hospitalisations, and 
adverse events. Neutropenia, skeletal complications and progressive disease are also 
especially costly in MM. This evidence highlights the need for effective therapies 
with improved tolerability profiles that delay progression across a broad range of 
patients with and without comorbidities.
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Objectives: The objective of this study was to assess the breadth and usefulness of 
information available in social media and patient-specific forums on indirect costs 
of a disease. MethOds: Internet searches of general social media and patient-spe-
cific forums were performed to identify sources of information on the indirect costs 
of breast cancer and schizophrenia. Results: Searches of general social media sites 
mainly resulted in posts related to available treatments, health awareness cam-
paigns, non-patient opinions and news articles, as well as irrelevant, often malicious 
posts, such as direct insults to schizophrenic patients. Fewer, but lengthier, posts 
were identified on patient forums, which could be an effective way of identifying 
indirect costs of the diseases. Such costs include time spent off work by the patient 
and their caregivers, delays in restoring independence such as being able to drive, 
and non-medical items used by women on chemotherapy. Breast cancer appears to 
be better represented than schizophrenia, possibly because patients with mental 
health problems face social stigma and thus don’t communicate their struggle as 
openly. Topics of conversation across forums include adverse treatment events and 
their associated costs, as well as other costs incurred by the patients due to their 
deteriorating health and quality of life. cOnclusiOns: This study looked at avail-
able information on the economic burden of breast cancer and schizophrenia on its 
patients and found that general social media appear to be less useful than patient 
forums. Depending on the disease being researched, different kinds of information 
become available and prove to be useful in drawing conclusions about the indirect 
costs of an illness. The breast cancer community appears to be better represented 
and more vocal about resource use associated with the disease or treatment than 
the schizophrenia community. The perspective of caregivers is less represented in 
breast cancer than schizophrenia.
